Cost-Effective Insulin Glargine Biosimilar Could Upend Reference Diabetes Drug; McKinsey Estimates Biosimilar Market Will Hit $30 Billion by 2025
The Food and Drug Administration (FDA) recently approved Semglee, an insulin glargine biosimilar product. Compared to reference drug Lantus, the [...]
New Study Considers Stakeholder Challenges in Orphan Drug Cost-Effectiveness
A recent article, published in the Journal of Managed Care and Specialty Pharmacy (JMCP), discusses the perspectives of providers, payers, [...]
Register Today for June 2nd ISPOR Short Course on HEOR and Cost-Effectiveness Analysis
ISPOR will hold a short course on June 2nd and 3rd designed to provide healthcare professionals information regarding new techniques [...]
Cost-Saving Oncology Pathways Evaluation Tool Now Available
A comparison tool allows users to effectively evaluate oncology pathways. Results include better quality of care, less variability in care, [...]
Tufts Cost-Effectiveness Analysis Registry Seeks Reviewers
The Center for the Evaluation of Value and Risk in Health at Tufts Medical Center maintains a Cost-Effectiveness Analysis (CEA) [...]
Report on International Healthcare Systems Notes High Costs in United States and Equity Challenges
The Commonwealth Fund has published a report that provides a comprehensive look into healthcare systems around the world. In the [...]
ISPOR Publishes Good Practices Report
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) task force has published its Good Practices Report. The purpose of [...]
ICER Reveals Final Evidence Report on Three Multiple Myeloma Therapies
The Institute for Clinical and Economic Review (ICER) has announced a Final Evidence Report evaluating three therapies for use in [...]
New Study Examines Cost-Effectiveness, Equity, Caregiver Burden, and Other Value Elements in 20 ICER Reports
A new article, published in the Journal of Managed Care and Specialty Pharmacy, examines 32 value elements, including health equity [...]
New Podcast Featuring ICER President on Consequences of High Drug Prices and Thoughts on New Cholesterol-Reducing Drugs
A recent Managed Healthcare Executive podcast featured ICER President and Founder Dr. Steven Pearson. ICER recently published a report on [...]
New ISPOR Value in Health Article on Applying HEOR to the COVID-19 Pandemic
A new editorial article published in ISPOR’s Value in Health journal discusses the positive and negative consequences pharmaceutical and nonpharmaceutical [...]
New ISPOR Good Practices Report Includes Guidelines for Cost Analyses
ISPOR has released a new report on how to conduct systematic reviews with cost and cost-effectiveness outcomes (SRs-CCEOs). Mandrik et [...]
New Report by Patient Coalition on Substandard Healthcare Plans Resulting in Patient Cost Burden
A coalition of 30 patient organizations advocating for healthcare access for patients with preexisting health conditions has released a new [...]
Two Online Decision Modelling Courses for Health Economists and Health Professionals
The London School of Hygiene & Tropical Medicine and the University of York have partnered to offer two online courses [...]
Comparing High US Drug Prices to Rest of World is Flawed, Reference Pricing Not a Solution
There are five key points driving high drug prices in the US, including better access in the US and robust [...]
Democratic and Republican Voters Agree on Lowering Extreme Drug Prices
A recent poll suggests that President Biden needs to take firm action on skyrocketing prescription drug prices. Prescription drug price [...]
Will Washington State Take on Drug Distribution Role?
A new bill would give the state of Washington’s Health Care Authority the power to distribute generic drugs and insulin [...]
Defining Low-Value Care and Improving Healthcare Cost-Effectiveness
A recent report, published in JAMA Health Forum, distinguishes between no-value care and low-value care. The authors ask five questions [...]
Understanding the Spectrum of Low-Value Care and Economic Implications
In a recent study, researchers compared over one thousand low-value care recommendations from five US healthcare organizations (USPSTF, ACP, ACC/AHA, [...]
Sarepta’s New Treatment for Duchenne Muscular Dystrophy Approved by FDA, $1 Million Yearly Cost Despite Lack of Confirmation Studies
Sarepta Therapeutics has created a third drug for use in Duchenne Muscular Dystrophy (DMD), termed Amondys 45. It recently received [...]
New Bills Propose High Taxes for Unjustified Drug Price Increases
Legislators in Washington and Hawaii have introduced bills aimed at drug price increases by pharmaceutical companies. Should these bills be [...]
NBER Releases Cost-Sharing Report: Drug Price Increases Associated With Increased Mortality
The National Bureau of Economic Research (NBER) has released a report on how cost-sharing affects patient care. The authors found [...]
Importing Prescription Drugs: What Does Biden Think?
According to former President Trump and current President Biden, Americans should be able to buy prescription drugs from other countries. [...]
Do Hospitals Actually Mark Up Medications 250%?
A recent report examines the cost differences regarding medications in hospitals. A comparison across two dozen drugs led to the [...]
Caesarean Section Procedure Can Vary in Price From 6k to 60k—At the Same Hospital
Women who undergo a caesarean section at the Van Ness site of the Pacific Medical Center in California might be [...]